Aspiriant LLC Sells 618 Shares of Danaher Co. (NYSE:DHR)

Aspiriant LLC decreased its holdings in Danaher Co. (NYSE:DHR) by 11.2% during the 4th quarter, Holdings Channel.com reports. The fund owned 4,896 shares of the conglomerate’s stock after selling 618 shares during the quarter. Aspiriant LLC’s holdings in Danaher were worth $1,124,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the stock. Decker Retirement Planning Inc. bought a new position in shares of Danaher during the 4th quarter valued at approximately $31,000. Teachers Insurance & Annuity Association of America bought a new stake in shares of Danaher during the third quarter valued at about $39,000. MidAtlantic Capital Management Inc. purchased a new stake in Danaher in the 3rd quarter worth approximately $40,000. FSA Wealth Management LLC bought a new stake in Danaher during the third quarter valued at $50,000. Finally, Darwin Wealth Management LLC purchased a new stake in shares of Danaher in the 3rd quarter valued at about $55,000. Institutional investors own 79.05% of the company’s stock.

Analyst Ratings Changes

DHR has been the topic of a number of research analyst reports. Raymond James decreased their price target on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. KeyCorp upped their price objective on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. Stifel Nicolaus upped their price objective on shares of Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research note on Wednesday, October 23rd. Royal Bank of Canada dropped their price target on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Finally, Scotiabank started coverage on shares of Danaher in a research report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price target for the company. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $286.80.

Danaher Price Performance

Shares of NYSE:DHR opened at $238.41 on Tuesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. Danaher Co. has a 1-year low of $222.53 and a 1-year high of $281.70. The company has a market capitalization of $172.20 billion, a P/E ratio of 45.50, a P/E/G ratio of 4.30 and a beta of 0.83. The firm’s 50 day simple moving average is $234.85 and its two-hundred day simple moving average is $253.51.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.14. The company had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. Danaher’s quarterly revenue was up 3.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.02 earnings per share. Research analysts expect that Danaher Co. will post 7.49 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be paid a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. The ex-dividend date is Friday, December 27th. Danaher’s payout ratio is 20.61%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.